Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Changing environment leads PPD to set up in Japan

This article was originally published in Scrip

Executive Summary

The US contract research company PPD has established a new direct presence in Japan. An office in Tokyo will provide Phase II to postmarketing clinical trial management services in response to growing demand in East Asia. There had been a significant increase in multinational studies including sites in Japan, the company said. Contrary to its past image as a slow and expensive place for clinical work, PPD's CEO Fred Eshelman said: "Japan offers competitive timelines for site start-up and patient enrolment, and the government is making major improvements to streamline drug development." These include a project to set up a national network of trial centres.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

SC001686

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel